Themis Medicare Limited has informed the Exchange regarding Resignation of Mr. Pradeep M. Chandan as Company Secretary & Compliance Officer of the company w.e.f. February 13, 2026.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare's board met on February 13, 2026 and approved several matters in one go. Standalone revenue for Q3 FY26 came in at ₹9,013.32 lakhs, slightly lower than ₹9,380.63 lakhs in Q3 FY25, while 9M FY26 standalone revenue dropped sharply to ₹26,570.50 lakhs from ₹33,381.00 lakhs a year ago, dragging the company to a 9-month standalone loss of ₹1,615.11 lakhs versus a profit of ₹3,166.63 lakhs earlier. Consolidated Q3 showed a profit of ₹1,009.36 lakhs, boosted by share of profit from associates. The company recorded two exceptional items: an ₹86.53 lakh hit from new Labour Codes and a ₹129.39 lakh write-off related to its UK subsidiary Carpo Medicals being struck off. Separately, Company Secretary and KMP Mr. Pradeep M. Chandan resigned citing other professional commitments, and Mr. Nagraj Mogaveera (currently Deputy CS) was appointed as Interim CS effective February 14, 2026. The board also approved issuing convertible equity warrants of up to 4.99% of share capital (45,95,795 shares) to promoter/promoter group via preferential allotment, and an inter-se transfer of up to 3% of GTBL shares within the promoter group at market price, with no change in overall promoter holding.
The 9-month loss reversal and sharp revenue decline are negative for shareholders, partly offset by an improved Q3 standalone profit and strong associate contribution. The CS exit is a routine KMP change with a replacement already in place, while the promoter warrant issue signals promoter confidence but will be dilutive once converted, subject to shareholder approval.